The Serum Institute of India is conducting the phase-three trial of the Oxford-AstraZeneca COVID-19 vaccine, while Bharat Biotech and ICMR has already started the phase-three trail of the indigenously developed COVAXIN jab. He told the British Broadcasting Corporation (BBC) on Thursday that he was "delighted" that early results show a strong immune response "even in those over 70 years of age".
So far, two companies developing COVID-19 vaccines, Pfizer/BioNTech and Moderna, have revealed analysis from late-stage studies of their respective candidates. Both vaccines require two doses, according to clinical trial registration data, according to Reuters.
"To show this vaccine technology is able to induce these responses, in the age group most at risk from severe COVID-19 disease, offers hope that vaccine efficacy will be similar in younger and older adults". "The Lancet Infectious Diseases" journal published the results of the initial trial. The vaccine uses a chimpanzee adenovirus which has been genetically modified to have the same external spike proteins as SARS-CoV-2, the virus behind Covid-19. The human cells will then create proteins to develop antibodies against the coronavirus.
FILE - A health worker talks to a vaccine trials' volunteer in Johannesburg, South Africa, August 27, 2020.
The Oxford study was briefly suspended in September because of an unexplained illness in a volunteer. These developments assume significance against the backdrop of Pfizer seeking emergency use authorisation of its COVID-19 vaccine from the USA regulators. The phase 3 trial was briefly put on pause before it restarted late last month.
We suspect that we will need as much help as we can get from PAHO which, fortunately, has been quite proactive in partnering with the Inter-American Development Bank, the European Union and other financial institutions and donors to secure the funding needed for lower income countries in the region to join COVAX.
Based on these interim safety and efficacy data, Moderna intends to submit for an Emergency Use Authorisation (EUA) with the US Food and Drug Administration (USFDA) in the coming weeks and anticipates having the EUA informed by the final safety and efficacy data.
Hai Do wrote this story for Learning English.